Compare NMTC & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMTC | MIRA |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 33.7M |
| IPO Year | N/A | 2023 |
| Metric | NMTC | MIRA |
|---|---|---|
| Price | $0.79 | $1.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.23 | N/A |
| AVG Volume (30 Days) | 252.9K | ★ 263.2K |
| Earning Date | 12-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,097,692.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $31.19 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 250.35 | N/A |
| 52 Week Low | $0.40 | $0.73 |
| 52 Week High | $1.39 | $2.45 |
| Indicator | NMTC | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 55.22 |
| Support Level | $0.65 | $1.44 |
| Resistance Level | $0.83 | $1.69 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 92.18 | 48.21 |
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.